Latest cutaneous T-cell lymphoma Stories
RnRMarketResearch.com adds "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2014" to its store.
PRINCETON, N.J., Jan. 7, 2015 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J., Nov. 17, 2014 /PRNewswire/ -- Soligenix, Inc.
RnRMarketResearch.com adds “Mycosis Fungoides and Leiomyosarcoma – Pipeline Review, H2 2014” to its store.
Pivotal Phase 3 Clinical Trial Targeted to Begin in First Half of 2015 PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Soligenix, Inc.
Newly Acquired SGX301 Orphan Drug Candidate Being Evaluated for Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 5, 2014 /PRNewswire/ -- Soligenix, Inc.
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC
Targeted drug aims to address high recurrence and lower survival in people with B-cell cancers. Raleigh, NC (PRWEB) March 10, 2014 The Non-Hodgkin’s
Mayo Clinic researchers say the identification of a mutated gene frequently found in Non-Hodgkin’s Lymphoma may open the door to new treatments. Raleigh, NC
The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.
- A poem in which the author retracts something said in an earlier poem.